81 related articles for article (PubMed ID: 33037036)
1. Further improvement in glycemic control after switching from exenatide two times per day to exenatide once-weekly autoinjected suspension in patients with type 2 diabetes: 52-week results from the DURATION-NEO-1 study.
Wysham CH; Rosenstock J; Vetter ML; Wang H; Hardy E; Iqbal N
BMJ Open Diabetes Res Care; 2020 Oct; 8(1):. PubMed ID: 33037036
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of autoinjected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: The DURATION-NEO-2 randomized clinical study.
Gadde KM; Vetter ML; Iqbal N; Hardy E; Öhman P;
Diabetes Obes Metab; 2017 Jul; 19(7):979-988. PubMed ID: 28205322
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes.
Wysham CH; Rosenstock J; Vetter ML; Dong F; Öhman P; Iqbal N
Diabetes Obes Metab; 2018 Jan; 20(1):165-172. PubMed ID: 28685973
[TBL] [Abstract][Full Text] [Related]
4. DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks.
Buse JB; Drucker DJ; Taylor KL; Kim T; Walsh B; Hu H; Wilhelm K; Trautmann M; Shen LZ; Porter LE;
Diabetes Care; 2010 Jun; 33(6):1255-61. PubMed ID: 20215461
[TBL] [Abstract][Full Text] [Related]
5. Five-year efficacy and safety data of exenatide once weekly: long-term results from the DURATION-1 randomized clinical trial.
Wysham CH; MacConell LA; Maggs DG; Zhou M; Griffin PS; Trautmann ME
Mayo Clin Proc; 2015 Mar; 90(3):356-65. PubMed ID: 25744115
[TBL] [Abstract][Full Text] [Related]
6. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.
Frías JP; Guja C; Hardy E; Ahmed A; Dong F; Öhman P; Jabbour SA
Lancet Diabetes Endocrinol; 2016 Dec; 4(12):1004-1016. PubMed ID: 27651331
[TBL] [Abstract][Full Text] [Related]
7. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes.
Kim D; MacConell L; Zhuang D; Kothare PA; Trautmann M; Fineman M; Taylor K
Diabetes Care; 2007 Jun; 30(6):1487-93. PubMed ID: 17353504
[TBL] [Abstract][Full Text] [Related]
8. Association among weight change, glycemic control, and markers of cardiovascular risk with exenatide once weekly: a pooled analysis of patients with type 2 diabetes.
Blonde L; Pencek R; MacConell L
Cardiovasc Diabetol; 2015 Feb; 14():12. PubMed ID: 25645567
[TBL] [Abstract][Full Text] [Related]
9. Safety of exenatide once weekly for 52 weeks in Japanese patients with type 2 diabetes mellitus.
Onishi Y; Koshiyama H; Imaoka T; Haber H; Scism-Bacon J; Boardman MK
J Diabetes Investig; 2013 Mar; 4(2):182-9. PubMed ID: 24843650
[TBL] [Abstract][Full Text] [Related]
10. Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents.
Buse JB; Sesti G; Schmidt WE; Montanya E; Chang CT; Xu Y; Blonde L; Rosenstock J;
Diabetes Care; 2010 Jun; 33(6):1300-3. PubMed ID: 20332351
[TBL] [Abstract][Full Text] [Related]
11. Once-weekly exenatide as adjunct treatment of type 1 diabetes mellitus in patients receiving continuous subcutaneous insulin infusion therapy.
Traina AN; Lull ME; Hui AC; Zahorian TM; Lyons-Patterson J
Can J Diabetes; 2014 Aug; 38(4):269-72. PubMed ID: 24797495
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of once-weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes over 84 weeks.
Diamant M; Van Gaal L; Stranks S; Guerci B; MacConell L; Haber H; Scism-Bacon J; Trautmann M
Diabetes Care; 2012 Apr; 35(4):683-9. PubMed ID: 22357185
[TBL] [Abstract][Full Text] [Related]
13. Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years.
Taylor K; Gurney K; Han J; Pencek R; Walsh B; Trautmann M
BMC Endocr Disord; 2011 Apr; 11():9. PubMed ID: 21529363
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of exenatide once weekly over 7 years in patients with type 2 diabetes: An open-label extension of the DURATION-1 study.
Philis-Tsimikas A; Wysham CH; Hardy E; Han J; Iqbal N
J Diabetes Complications; 2019 Mar; 33(3):223-230. PubMed ID: 30600137
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the Use of Exenatide Once-Weekly Suspension Autoinjector Among Patients With Type 2 Diabetes Mellitus and Health Care Professionals.
LaRue S; Springer J; Noderer M; Meehan J; Wysham CH
J Diabetes Sci Technol; 2019 Mar; 13(2):226-234. PubMed ID: 30234374
[TBL] [Abstract][Full Text] [Related]
16. Addition of thiazolidinedione or exenatide to oral agents in type 2 diabetes: a meta-analysis.
Pinelli NR; Cha R; Brown MB; Jaber LA
Ann Pharmacother; 2008 Nov; 42(11):1541-51. PubMed ID: 18957626
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea.
Bergenstal R; Lewin A; Bailey T; Chang D; Gylvin T; Roberts V;
Curr Med Res Opin; 2009 Jan; 25(1):65-75. PubMed ID: 19210140
[TBL] [Abstract][Full Text] [Related]
18. Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing.
Rosenstock J; Reusch J; Bush M; Yang F; Stewart M;
Diabetes Care; 2009 Oct; 32(10):1880-6. PubMed ID: 19592625
[TBL] [Abstract][Full Text] [Related]
19. Long-term effects of adding exenatide to a regimen of metformin and/or sulfonylurea in type 2 diabetes: an uncontrolled, open-label trial in Hungary.
Iványi T; Fövényi J; Faludi P; Han J; Macconell L; Wille S; Kiljanski J
Clin Ther; 2012 Jun; 34(6):1301-13. PubMed ID: 22608106
[TBL] [Abstract][Full Text] [Related]
20. Baseline factors associated with glycemic control and weight loss when exenatide twice daily is added to optimized insulin glargine in patients with type 2 diabetes.
Rosenstock J; Shenouda SK; Bergenstal RM; Buse JB; Glass LC; Heilmann CR; Kwan AY; MacConell LA; Hoogwerf BJ
Diabetes Care; 2012 May; 35(5):955-8. PubMed ID: 22432107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
